Pembrolizumab in combination with ipilimumab as second-line or later therapy for advanced non–small-cell lung cancer: KEYNOTE-021 cohorts D and H

Matthew A. Gubens, Lecia V. Sequist, James P. Stevenson, Steven F. Powell, Liza C. Villaruz, Shirish M. Gadgeel, Corey J. Langer, Amita Patnaik, Hossein Borghaei, Shadia I. Jalal, Joseph Fiore, Sanatan Saraf, Harry Raftopoulos, Leena Gandhi

Research output: Contribution to journal › Article › peer-review

72 Scopus citations

Fingerprint

Dive into the research topics of 'Pembrolizumab in combination with ipilimumab as second-line or later therapy for advanced non–small-cell lung cancer: KEYNOTE-021 cohorts D and H'. Together they form a unique fingerprint.

Pharmacology, Toxicology and Pharmaceutical Science